Search all trials

Find therapies in clinical trials near you – page 8

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study of Amivantamab, Lazertinib, and Pemetrexed for Patients with Advanced or Metastatic Solid Tumors, Including EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Amivantamab

Contact Research Centre

Non-small cell lung cancer

Recruiting

InvestigationalNo placebo

Study of NVL-520 for Patients with Advanced ROS1-Positive Lung Cancer and Other Solid Tumors

InvestigationalNo placebo

Belgium

Participants:0–17 years · 18–64 years · 65+ years
Substances:Zidesamtinib

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Nivolumab, Pembrolizumab, and Cemiplimab with Radiotherapy for Stage IV Non-Small Cell Lung Cancer Patients

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Registered drugNo placebo

Study on the Safety and Effects of Divarasib with Pembrolizumab and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Budesonide

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drug

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Mk-1084

Contact Research Centre

Non-small cell lung cancer+3

Recruiting

Registered drugNo placebo

Study on Durvalumab with Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer Patients

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study of RMC-6291 and Pembrolizumab with or without Chemotherapy for Patients with Advanced KRAS G12C Mutated Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Non-small cell lung cancer+2

Recruiting

Registered drugNo placebo

Study on Preoperative Treatment with Amivantamab, Carboplatin, and Pemetrexed for Patients with Resectable Non-Small-Cell Lung Cancer with EGFR Mutations

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Amivantamab

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Infliximab

Contact Research Centre

Non-small cell lung cancer+12

Recruiting

Registered drugNo placebo

Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Temozolomide

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study of RMC-6236 and Pembrolizumab with or without Chemotherapy for Patients with RAS-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Non-small cell lung cancer+2

Recruiting

Registered drugNo placebo

Study on THIO and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Cemiplimab

Contact Research Centre

Find therapies in clinical trials near you – page 8

325 trials match your criteria

Non-small cell lung cancer

Study of Amivantamab, Lazertinib, and Pemetrexed for Patients with Advanced or Metastatic Solid Tumors, Including EGFR-Mutated Non-Small Cell Lung Cancer

Non-small cell lung cancer

Study of NVL-520 for Patients with Advanced ROS1-Positive Lung Cancer and Other Solid Tumors

Non-small cell lung cancer

Study on the Safety and Effectiveness of Nivolumab, Pembrolizumab, and Cemiplimab with Radiotherapy for Stage IV Non-Small Cell Lung Cancer Patients

Non-small cell lung cancer+1

Study on the Safety and Effects of Divarasib with Pembrolizumab and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation

Non-small cell lung cancer

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Non-small cell lung cancer+3

Study on Durvalumab with Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer Patients

Non-small cell lung cancer

Study of RMC-6291 and Pembrolizumab with or without Chemotherapy for Patients with Advanced KRAS G12C Mutated Lung Cancer

Non-small cell lung cancer+2

Study on Preoperative Treatment with Amivantamab, Carboplatin, and Pemetrexed for Patients with Resectable Non-Small-Cell Lung Cancer with EGFR Mutations

Non-small cell lung cancer

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Non-small cell lung cancer+12

Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers

Non-small cell lung cancer

Study of RMC-6236 and Pembrolizumab with or without Chemotherapy for Patients with RAS-Mutated Non-Small Cell Lung Cancer

Non-small cell lung cancer+2

Study on THIO and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.